Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
0.7936
+0.0016 (0.20%)
At close: Aug 20, 2026, 4:00 PM EDT
0.7936
0.00 (0.00%)
After-hours: Aug 20, 2026, 4:11 PM EDT

Rein Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
683050151151
Market Cap Growth
157.77%-38.81%234.56%38.39%-78.89%20.50%
Enterprise Value
2771773-15-1
Last Close Price
0.791.162.303.052.3711.26

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
6.661.800.920.150.581.16
P/TBV Ratio
----0.581.16

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
---00.000.00
Net Debt / Equity Ratio
-0.74-0.19-0.24-0.18-1.14-1.04
Net Debt / EBITDA Ratio
1.960.150.461.130.771.73
Net Debt / FCF Ratio
2.160.170.580.870.851.91
Quick Ratio
4.190.522.243.956.2810.19
Current Ratio
4.270.702.384.176.4610.69
Return on Equity (ROE)
-96.42%-139.87%-82.37%-26.91%-87.41%-93.33%
Return on Assets (ROA)
-21.02%-31.75%-20.89%-14.99%-49.03%-51.30%
Return on Capital Employed (ROCE)
-36.90%-122.00%-49.80%-15.10%-148.50%-60.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-67.83%-163.55%-126.19%-105.62%-253.93%-51.32%
FCF Yield
-25.67%-63.50%-44.73%-132.99%-231.03%-46.90%
Buyback Yield / Dilution
-71.24%-41.84%-290.09%-1.31%-2.23%-154.70%
SEC Filings: 10-K · 10-Q